Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (SANN.SW) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Santhera Pharmaceuticals Holding AG (SANN.SW), featuring income statements, balance sheets, and cash flow data.
Santhera Pharmaceuticals Holding AG (SANN.SW) Income Statement & Financial Overview
Analyze Santhera Pharmaceuticals Holding AG’s SANN.SW earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $25.003M | $14.11M | $99.44M | $49.72M |
| Cost of Revenue | $10.66M | $5.21M | $1.64M | $653500.00 |
| Gross Profit | $14.34M | $8.90M | $97.80M | $49.06M |
| Gross Profit Ratio | $0.57 | $0.63 | $0.98 | $0.99 |
| R&D Expenses | $12.70M | $13.77M | $8.93M | $4.46M |
| SG&A Expenses | $17.23M | $12.93M | $18.03M | $9.18M |
| Operating Expenses | $29.93M | $26.64M | $26.95M | $2.73M |
| Total Costs & Expenses | -$40.59M | $31.86M | $28.59M | $3.39M |
| Interest Income | $11.14M | $0.00 | $0.00 | $12.68M |
| Interest Expense | $16.14M | $0.00 | $25.36M | $0.00 |
| Depreciation & Amortization | $2.87M | $2.77M | $1.22M | $607500.00 |
| EBITDA | -$1.40M | -$14.97M | $92.75M | $36.32M |
| EBITDA Ratio | -$0.06 | -$1.06 | $0.72 | $0.73 |
| Operating Income | -$15.59M | -$17.74M | $70.85M | $35.71M |
| Operating Income Ratio | -$0.62 | -$1.26 | $0.71 | $0.72 |
| Other Income/Expenses (Net) | -$10.99M | $2.65M | $7.39M | -$5.45M |
| Income Before Tax | -$26.57M | -$15.09M | $78.24M | $39.12M |
| Income Before Tax Ratio | -$1.06 | -$1.07 | $0.79 | $0.79 |
| Income Tax Expense | $138000.00 | $174000.00 | $123000.00 | $61500.00 |
| Net Income | -$26.71M | -$15.26M | $78.12M | $39.06M |
| Net Income Ratio | -$1.07 | -$1.08 | $0.79 | $0.79 |
| EPS | -$2.34 | -$1.35 | $7.00 | $3.50 |
| Diluted EPS | -$2.34 | -$1.35 | $7.00 | $3.50 |
| Weighted Avg Shares Outstanding | $0.00 | $11.34M | $11.16M | $11.16M |
| Weighted Avg Shares Outstanding (Diluted) | $0.00 | $11.34M | $11.16M | $11.16M |
Over the last four quarters, Santhera Pharmaceuticals Holding AG's revenue moved from $49.72M in Q3 2023 to $25.003M in Q4 2024. Operating income in Q4 2024 was -$15.59M, with a strong operating margin of -62%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Santhera Pharmaceuticals Holding AG remained robust at -$1.40M, reflecting operational efficiency. Net income dropped to -$26.71M, with an EPS of -$2.34. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan